Redeye sees the amyloid-beta hypothesis greatly strengthened with FDA's approval of aducanumab today. The human antibody is promoted by Biogen and Eisai, which also promote BioArctic's lecanemab, a humanized monoclonal antibody targeting the toxic forms of amyloid-beta. We maintain our fair value per share of SEK 208 for BioArctic, and our view that the stock is greatly undervalued.